DIALYSIS-TIR Study (NCT06042153) | Clinical Trial Compass
Active — Not RecruitingPhase 4
DIALYSIS-TIR Study
United States43 participantsStarted 2023-12-05
Plain-language summary
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly.
Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 days at five different time points during the study.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Ability to provide informed consent before any trial-related activities. Trial-related activities are any procedures that are carried out as a part of trial, including activities to determine suitability for the trial.
. Male or female Adults (age \> 18 years at the time of signing the consent)
. Type 2 diabetes mellitus diagnosed \> 6 months prior to screening
. On current chronic treatment with Hemodialysis or Peritoneal dialysis for \> 6 months prior to screening
. Current treatment with any glucose lowering pharmacotherapy, at a stable dose for at least 30 days. DPP-4 Inhibitors will be allowed at study entry and will be stopped at randomization.
. Minimum of 80% valid data on the 10-day Continuous Glucose Monitor download
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in TIR (70-180 mg/dl)
Timeframe: Baseline, 52 weeks
Trial details
NCT IDNCT06042153
SponsorUniversity of Texas Southwestern Medical Center
. Current (within the past 90 days of screening) use of any GLP-1 RA
. Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2
. Known or suspected hypersensitivity to GLP-1 RA (trial medication(s), excipients, or related products)
. Pregnant, breast-feeding or the intention of becoming pregnant, or not using effective contraceptive measures
. Active weight loss, defined as weight loss of \>5% of body weight in the past 3 months
. Current participation in other interventional trials or last dose of any investigational product within 4 half- lives at the time of randomization
. Any medical condition which in the judgement of the investigator precludes safe participation in the trial (includes, but not limited to active neoplasm, severe heart failure, recent cardiovascular event, severe frailty, planned cardiac or vascular surgeries on the day of screening etc)